KCNH2-3.1 potassium channel and schizophrenia.

KCNH2-3.1 钾通道与精神分裂症。

• 批准号: 8848140
• 负责人: Feng Yang
• 金额: $ 30.53万
• 依托单位: LIEBER INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-15 至 2019-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8848140
• 关键词: Action Potentials; Acute; Adolescent; Adult; Animal Model; Animals; Antipsychotic Agents; Behavioral; Biological Assay; Biological Neural Networks; Brain; Brain imaging; Cells; Clinical; Cognitive; Cognitive deficits; Complex; Data; Dendritic Spines; Deterioration; Development; Early treatment; Electroencephalography; Elements; Etiology; Fluo 4; Functional disorder; Genes; Genetic; Genetic Risk; Health; Hereditary Disease; Heritability; Hippocampus (Brain); Human; Image; Imaging technology; Impairment; In Vitro; Individual; Intervention; Location; Long-Term Potentiation; Medial; Mediating; Memory; Memory impairment; Microscope; Modeling; Molecular; Monkeys; Mus; Mutant Strains Mice; Neurobiology; Neuronal Dysfunction; Neurons; PHluorin; Pathogenesis; Patients; Pattern; Performance; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phenotype; Physiological; Potassium Channel; Prefrontal Cortex; Prevalence; Preventive; Primates; Protein Isoforms; Public Health; Publishing; Pyramidal Cells; Role; Schizophrenia; Seminal; Short-Term Memory; Signal Pathway; Slice; Societies; Susceptibility Gene; Synapses; System; Testing; Therapeutic Agents; Therapeutic Intervention; Time; Tissues; Transgenic Mice; Work; awake; basal forebrain; base; behavior test; biomedical scientist; cholinergic; drug development; emerging adult; hippocampal pyramidal neuron; in vitro activity; in vivo; memory recognition; molecular imaging; mutant; nerve supply; nervous system disorder; neural circuit; novel; novel therapeutics; object recognition; phenomenological models; presynaptic; relating to nervous system; response; temporal measurement; transmission process; treatment strategy

DESCRIPTION (provided by applicant): Schizophrenia is a debilitating neurological disorder with a world-wide prevalence of 1%. There is a strong genetic component with an estimated heritability of 80-85%. In the last decade, there has been unprecedented progress in identifying schizophrenia susceptibility genes, but the effect sizes of individual genes have been meager. Earlier studies have suggested that a primate and brain selective isoform (3.1) of the KCNH2 potassium channel is a factor in the brain dysfunction associated with schizophrenia. However, the critical molecular, cellular and neural network mechanisms related to KCNH2-3.1 and their relationship to the pathogenesis of schizophrenia are largely unknown. A KCNH2-3.1 isoform transgenic mouse has recently been made. This study defines the role of KCNH2-3.1 in the development of schizophrenia related cortical circuits, and illuminates critical issues in the time course of schizophrenia and provides support for a clinically important early treatment strategy and drug development. To test the central hypothesis that KCNH2-3.1 represents a key element not only for acute changes in cell firing patterns but also for long-term aberrant neurobiology by enhancing intrinsic neuronal vulnerability and the formation of impaired neural connections, the following three specific aims will be carried out: (1) In vitro electrophysiologicl and imaging studies of tissues taken from animal with extensive behavioral and cognitive phenotype will identify whether deficits in both sustained neuronal firing and neuronal synchronized activity in the prefrontal cortex (PFC) contribute to working memory deficits in the KCNH2-3.1 mice. Neuronal sustained firing and synchronized activity in the PFC are thought to reflect the cellular mechanisms critical for working memory dysfunction, which is considered to be a core feature of schizophrenia. (2) In vitro brain slices prepared from animals with extensive behavioral and cognitive phenotypes will be examined to determine whether behavioral deficits in these mice as adults reflect long-term dysfunction of neuronal structural plasticity in the PFC and hippocampus. (3) Telemetric EEG recording, the pHluorin assay and Inscopix's miniature in vivo brain imaging technology will be applied to determine whether selective impairments in neural connections between hippocampus and mPFC develop in these mice, as has also been implicated in schizophrenia. In addition, this work will answer the following questions: what are the time window changes in altering dendritic spines of prefrontal cortex and hippocampus described in these mice? What time window is best for antipsychotic drugs intervention? Which intracellular signaling pathways are involved in KCNH2-3.1-mediated structural plasticity and working memory deficits? Answers to these questions will identify targets for early therapeutic intervention that may be an effective way to avoid progressive synaptic structural and behavioral deterioration in patients with schizophrenia. The neural circuit studies in mutant KCNH2-3.1 mice will also be important and necessary for developing new drug treatments based on causation rather than phenomenology.

描述（由申请人提供）：精神分裂症是一种衰弱性神经系统疾病，全球患病率为1%。有很强的遗传成分，估计遗传率为80-85%。在过去的十年中，在识别精神分裂症易感基因方面取得了前所未有的进展，但个体基因的影响规模仍然微不足道。早期的研究表明，灵长类动物和大脑选择性的KCNH2钾通道亚型（3.1）是与精神分裂症相关的脑功能障碍的一个因素。然而，与KCNH2-3.1相关的关键分子、细胞和神经网络机制及其与精神分裂症发病机制的关系在很大程度上是未知的。一个KCNH2-3.1异构体转基因小鼠最近被制造出来。本研究明确了KCNH2-3.1在精神分裂症相关皮质回路发育中的作用，并阐明了当时的关键问题